Esperion to Participate in The 2026 Citizens Life Sciences Conference
Esperion (NASDAQ: ESPR) will participate in the 2026 Citizens Life Sciences Conference on March 11, 2026, presenting at 8:25 a.m. ET.
Rhea-AI Summary
Esperion (NASDAQ: ESPR) will participate in the 2026 Citizens Life Sciences Conference on March 11, 2026, presenting at 8:25 a.m. ET. The presentation will be webcast live and accessible via the company’s investor and media website. A replay will be available about two hours after the call and archived for approximately 90 days.
Positive
- None.
Negative
- None.
Details
News Market Reaction – ESPR
On Feb 18, the day this news came out, ESPR closed 0.56% above the previous close.
Data tracked by StockTitan Argus for the Feb 18 session.
Key Figures
- Conference date
- March 11, 2026
- Citizens Life Sciences Conference participation
- Presentation time
- 8:25 a.m. ET
- Scheduled conference webcast start time
- Webcast replay delay
- approximately two hours
- Delay before replay becomes available after call completion
- Replay archive period
- approximately 90 days
- Duration replay will remain on company website
Historical Context
-
Settlement with Alkem limiting U.S. generics for NEXLETOL/NEXLIZET until 2040.
-
Grant of 40,200 RSUs to 11 new employees under inducement plan.
-
Preliminary 2025 results and long-term Vision 2040 growth strategy at JPM conference.
-
Announcement of presentation and fireside chat at J.P. Morgan Healthcare Conference.
-
Bempedoic acid recommended in 2025 ACC statement for PAD with diabetes.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ANN ARBOR, Mich., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted 2026 Citizens Life Sciences Conference on March 11, 2026, at 8:25 a.m. ET.
The live webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company’s website for approximately 90 days.
About Esperion Therapeutics
Esperion Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and delivering innovative cardiometabolic and rare/orphan disease therapies. The Company leverages deep domain expertise in ACLY biology to develop and commercialize transformative medicines for patients worldwide. Esperion currently markets two oral, once-daily, non-statin therapies for patients struggling to maintain their low-density lipoprotein cholesterol (LDL-C) levels and are at risk of cardiovascular disease.
With a broad U.S. commercial infrastructure and global approvals across more than 40 countries, Esperion is well positioned to serve as a partner-of-choice for global innovators seeking U.S. market access through acquisition, in-license, co-promotion and revenue share opportunities. In tandem, the Company is advancing its leadership in ACLY biology to build a diversified pipeline of novel product candidates, including treatments for Primary Sclerosing Cholangitis and renal diseases. For more information, visit esperion.com and follow Esperion on LinkedIn and X.
Esperion Contact Information:
Investors:
Alina Venezia
investorrelations@esperion.com
(734) 887-3903
Media:
Tiffany Aldrich
corporateteam@esperion.com
(616) 443-8438
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.